Screener / SEC EDGAR /CIK 0001520697 /10-K filed Feb 27, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Specialty Outpatient Facilities

Acadia Healthcare Company, Inc. ACHC

Compare with peers Embed
SEC comment letters, last 20 years

6 reviews of ACHC's filings by SEC staff

UPLOAD and CORRESP
Reviews 6 latest letter Feb 12, 2025
Questions asked 11 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 7 UPLOAD
  2. 2. Questions in them 11 numbered comments
  3. 3. Company replies 9 CORRESP
  4. 4. Reviews closed 4 of 6 closing letter

Half the closed reviews took 26 days or less from the first letter to the closing letter.

Form 8-K

2025-02-12 to 2025-02-18 · 1 question · 1 letter from the SEC, 1 from the company
No closing letter
Non-GAAP measures
After reviewing your response to this letter, we may have additional comments. Exhibit 99, page 10
SEC asked
We note the draft disclosures you provided in response to comment 2. Please expand these disclosures to provide a more fulsome discussion of your Same Facility Results and Facility Results to address the following: • Clearly explain the purpose and what you are trying to convey for each presentation.
Rest of the question

• Discuss the limitations of these presentations, especially as it relates to Adjusted EBITDA; an explanation about how you address these limitations; and a statement that the presentations should not be used to evaluate your performance as a whole. • For the adjustments to arrive at Same Facility Adjusted EBTIDA and Facility Adjusted EBITDA, provide a more robust discussion of the nature of the specific costs being excluded and how you determined these costs.

ACHC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company has modified the draft presentation previously provided in Annex C to the Company’s response to the Staff’s letter, dated December 20, 2024

(such response, the “Prior Response Letter”), as reflected in Annex C hereto, to provide further discussion of the Company’s presentation of facility and same facility results.
Rest of the answer

Further, the

Company has modified the draft presentation previously provided in Annex A to the Prior Response Letter, as reflected in Annex A hereto, to add additional disclosure relating to the facility and same facility results, and the Company has modified the draft presentation previously provided in Annex B to the Prior Response Letter, as reflected in Annex B hereto, to update one line item and certain footnote references.

Additionally, the Company advises the Staff that, beginning with its next earnings release, which will be for the fiscal year ending

December 31, 2024, it will modify the note beneath the “Highlights” section on the first page of its earnings release, and such note will be presented similarly to the below, as applicable (additions italicized and deletions indicated with strikethrough):

Adjusted income attributable to Acadia, and Adjusted EBITDA and

Same Facility Adjusted EBITDA are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page [X].

Read in the reply

Form 10-K

2024-11-15 to 2025-02-20 · 3 questions · 2 letters from the SEC, 3 from the company
Review closed 2025-02-20
Non-GAAP measuresResults discussion (MD&A)Legal and contingenciesDerivatives and hedging
Operations · Results of Operations, page 37
SEC asked
We note your presentation of Adjusted EBITDA margin change and Adjusted EBITDA margin excluding income from provider relief fund, which appear to be non- GAAP performance measures. Please expand your disclosures to fully comply with the disclosure requirements in Item 10(e)(1)(i) of Regulation S-K. 11: Commitments and Contingencies, page F-21 We note your disclosures for Securities Litigation and Derivative Actions.
Rest of the question

Please expand your disclosures to state the amount or range of reasonably possible loss in the aggregate, or that you are unable to reasonably estimate the amount or range. Please note that ASC 450-20-50-4 does not require the amount or range of reasonably 2. possible loss to be estimated with precision or certainty. Exhibit 99 3. We note your presentation of the change in Adjusted EBITDA within the Fourth Quarter Highlights section and also your presentation of Adjusted EBITDA margin and Adjusted EBITDA margin excluding income from provider relief fund without also presenting with equal or greater prominence the change in the most comparable US GAAP measure. Please revise these presentations to comply with the guidance in Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10(a) of the Compliance and Disclosure Interpretations for Non-GAAP Financial Measures. 4. We note your presentation of a net leverage ratio using Adjusted EBITDA as the denominator without also presenting with equal or greater prominence the calculation of net leverage ratio using the most comparable US GAAP measure. Please revise this presentation to comply with the guidance in Item 10(e)(1)(i)(A) of Regulation S- K and Question 102.10(a) of the Compliance and Disclosure Interpretations for Non- GAAP Financial Measures. 5. Please tell us and expand your disclosures for the transaction, legal and other costs adjustment to your various non-GAAP performance measures to clearly explain and quantify each component.

ACHC answered
On behalf of Acadia

Healthcare Company, Inc. (the “Company”), we acknowledge receipt of your letter (the “Comment Letter”), dated November 15, 2024, with respect to the Company’s Form 10-K for the fiscal year ended December 31, 2023, filed on February 27, 2024 (File No. 001-35331), and Form 8-K, filed on February 27, 2024 (File No. 001-35331), in which you requested that we respond within ten business days or advise you when we would provide a response. We have begun to analyze the comments of the staff of the U.S.
Rest of the answer

Securities and Exchange Commission and the Company is in the process of preparing a response. We respectfully request an extension of five business days so that we may devote the appropriate amount of time and resources to ensure a sufficient response. The Company will provide a comprehensive response to the Comment Letter no later than December 6, 2024.

Read in the reply
In its next report

First report after the company's reply of Nov 25, 2024: 10-K filed Feb 27, 2025 ↗, against the 10-K filed Feb 28, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 8-K Filed February 27, 2024 · Exhibit 99
SEC asked (1)
We note your response to prior comment 3, along with the draft presentations provided in Annexes A through C. In Annex B, please present Profit margin with equal or greater prominence of your presentation of Adjusted EBITDA margin.
ACHC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company has determined to no longer present adjusted EBITDA margin in future filings. As such, the Company has modified the draft presentation of Operating Statistics included as Annex A to the Company’s response to the Staff’s letter, dated November 15, 2024 (such response, the “Prior Response Letter”), to remove the Company’s presentation of profit margin and adjusted EBITDA margin, and the Company intends to present its Operating Statistics in future earnings releases and periodic reports as reflected
Rest of the answer

in Annex A hereto, which now includes same facility results and facility results for adjusted EBITDA. As a result of such modifications, the Company has revised its draft presentation of reconciliations previously presented in Annex B to the Prior Response Letter, as reflected in Annex B hereto, which revised presentation also includes applicable reconciliations previously included in Annex C to the Prior Response Letter. Accordingly, the Company has deleted the standalone draft presentation previously provided in Annex C to the Prior Response

Letter.

Read in the reply
In its next report

First report after the company's reply of Jan 21, 2025: 10-K filed Feb 27, 2025 ↗, against the 10-K filed Feb 28, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 8-K Filed February 27, 2024 · Exhibit 99
SEC asked (2)
In Annex A, we note your presentations of same facility results and facility results for profit margin, adjusted EBITDA margin, profit margin excluding income from provider relief fund, and adjusted EBTIDA margin excluding income from provider relief fund, all of which are non-GAAP measures. Please revise the title of profit margin to clearly identify it as a non-GAAP measure for both presentations.
Rest of the question

Please expand the associated reconciliations provided in Annex C to begin with the most directly comparable US GAAP measure and provide us with the revised reconciliations. Refer to Item 10(e)(1)(i)(B) of Regulation S-K for guidance. We note your response to prior comment 5, which provides the same information in 3. Note 16 to your third quarter of fiscal year 2024 Form 10-Q. As previously requested, please provide us with a comprehensive explanation, including quantification, for each of the components included in the transaction, legal and other costs adjustment to your various non-GAAP performance measures and provide expand disclosures for the adjustment.

ACHC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company has modified the draft presentation previously provided in Annex A to the Prior Response Letter, as reflected in Annex A hereto, to remove the Company’s presentation of same facility results and facility results for profit margin, adjusted EBITDA margin, profit margin excluding income from provider relief fund, and adjusted EBITDA margin excluding income from provider relief fund. Additionally, as detailed in the Company’s response to Comment No.
Rest of the answer

1 above, the Company has removed the draft presentation previously provided in Annex C to the Prior Response Letter because the Company has moved the reconciliations provided therein that remain applicable to the draft presentation in Annex B hereto. The Company respectfully advises the Staff that the Company’s reconciliation of net income attributable to Acadia Healthcare Company, Inc. to same facility adjusted EBITDA and same facility adjusted EBITDA excluding income from provider relief fund is included in

Annex B hereto.

Read in the reply
In its next report

First report after the company's reply of Jan 21, 2025: 10-K filed Feb 27, 2025 ↗, against the 10-K filed Feb 28, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: company letter, Dec 6, 2024, request for more time, Dec 23, 2024, closing letter, 2025-02-20

Form 10-K for the Fiscal Year Ended December 31, 2019

2020-09-25 to 2020-10-21 · 3 questions · 1 letter from the SEC, 1 from the company
Review closed 2020-10-21
Results discussion (MD&A)SegmentsRevenueGoodwill and impairmentCritical estimates
Results of Operations · Segments, page 49
SEC asked (1)
We note that you present changes in same facility operating data for the United Kingdom segment excluding the elderly care division. Please tell us and revise your future filings to disclose the rationale for excluding your elderly care division and quantify and disclose the impact of excluding it from your same facility results.
Rest of the question

Otherwise, to the extent your elderly care division did not have a meaningful impact on your same facility operating data; please disclose that fact in your filing.

ACHC answered
The elderly care division in the United Kingdom (“U.K.”) does not have a meaningful impact on our same facility operating data and trends and accounts for approximately 10% of U.K. revenue and approximately 1% of U.K. EBITDA. While the elderly care division is complementary to our continuum of behavioral healthcare services, it has never been part of our overall growth strategy nor had a meaningful impact on our operations or results. Therefore, we have consistently excluded the elderly care division from our U.K.
Rest of the answer

same facility results since we acquired it as part of a larger acquisition in 2016.

In future filings, commencing with our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, we will disclose within Management’s Discussion and Analysis of Financial

Condition and Results of Operations our rationale for exclusion of the elderly care division from our U.K. same facility results and that the elderly care division does not have a meaningful impact on our same facility operating data and trends.

Read in the reply
Results of Operations · Segments, page 49
SEC asked (2)
We note that while the United Kingdom same facility results saw revenue growth, total revenue and EBITDA margin for this segment decreased during the fiscal year. Please tell us and revise future filings to explain the additional factors that contributed to these decreases to provide a complete picture of the trends in your segments results.
Rest of the question

Refer to Item 303(A)(3)(ii) of Regulation S-K and Section III.B.3 of our Release No. 33-8350.

ACHC answered
U.K. same facility results are presented on a constant currency basis as disclosed in footnote (c) on page 49 of the 2019 Form 10-K in order to report operating trends without the impact of changes in foreign currency exchange rates. Conversely, segment revenue and segment EBITDA in our Segment Information footnote on page F-34 of the 2019 Form 10-K are presented in the reporting currency (U.S. dollar, “USD”) and not on a constant currency basis. Accordingly, U.K.
Rest of the answer

total revenue and EBITDA as presented in the Segment Information footnote are impacted by changes in the British pound (“GBP”) to USD exchange rate. For the years ended December 31, 2019 and 2018, changes in the GBP to USD exchange rate impacted revenue by $(48.0) million and $36.2 million, respectively, as disclosed on pages 50 and 51 of the 2019 Form 10-K.

As disclosed in footnote (e) on page 49 of the 2019 Form 10-K, for the years ended December 31, 2019 and 2018, U.K. EBITDA margin was negatively affected by lower census and higher operating expenses, including labor costs in particular. For the year ended December 31, 2018, contract labor costs in our U.K. Facilities were higher primarily as a result of the nursing and clinical labor shortage and our dependence on higher cost agency labor, which is disclosed on page 50 (within salaries, wages and benefits) of the 2019 Form 10-K.

We will ensure that future filings include disclosure of factors that impact segment results.

Critical Accounting Policies

Goodwill and Indefinite-Lived Intangible Assets, page 60

We note that you recorded a $325.9 million goodwill impairment for the United Kingdom facilities during the year ended December 31, 2018. For each reporting unit that is at risk of failing step one of the goodwill impairment, please revise your MD&A in future filings to provide the percentage by which your fair value exceeded the carrying value as of the date of the most recent test and describe any potential events and/or changes in circumstances, such as the recent pandemic, that could reasonably be expected to negatively affect any key assumptions. If you have determined that the estimated fair value substantially exceeds the carrying value of your reporting units, please disclose such determination. Refer to Section V of SEC Release 33-8350.

Response:

As of our most recent impairment test on October 1, 2019, the fair value of our U.S. Facilities reporting unit substantially exceeded its carrying value, and the fair value of our U.K. Facilities reporting unit exceeded its carrying value by approximately 7%.

We expanded our disclosures regarding the impact of COVID-19 on the fair value of our reporting units on page 40 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (Critical Accounting Policies, page 40).

In future filings, commencing with our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, we will include the percentage by which our fair value exceeds the carrying value of our U.K. Facilities reporting unit and will continue to evaluate and describe any potential events or changes in circumstances that could reasonably be expected to negatively affect our key assumptions. We will also disclose when a reporting unit’s fair value substantially exceeds its carrying value.

In the event that you have any additional questions, please feel free to contact the undersigned at (615) 861-6000.

Read in the reply
Critical Accounting Policies · Goodwill and Indefinite-Lived Intangible Assets, page 60
SEC asked (3)
We note that you recorded a $325.9 million goodwill impairment for the United Kingdom facilities during the year ended December 31, 2018. For each reporting unit that is at risk of failing step one of the goodwill impairment, please revise your MD&A in future filings to provide the percentage by which your fair value exceeded the carrying value as of the date of the most recent test and describe any potential events
Rest of the question

and/or changes in circumstances, such as the recent pandemic, that could reasonably be expected to negatively affect any key assumptions. If you have determined that the estimated fair value substantially exceeds the carrying value of your reporting units, please disclose such determination. Refer to Section V of SEC Release 33-8350.

ACHC answered

No numbered answer found in the reply. Read the reply ↗

In its next report

First report after the company's reply of Oct 8, 2020: 10-Q filed Oct 30, 2020 ↗, against the 10-Q filed Aug 5, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-10-21

Form 10-K for the Fiscal Year Ended December 31, 2017

2018-06-26 to 2018-07-12 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2018-07-12
RevenueSegmentsResults discussion (MD&A)Reserves and insurance
Year Ended December 31, 2017 Compared to the Year Ended December 31, 2016 · Year Ended December 31, 2016 Compared to the Year Ended December 31, 2015, page 47
SEC asked (1)
We note that you do not provide a separate discussion of your segments' operating results and pertinent statistical data but include such information in greater detail in your earnings release. In light of significant differences in the revenue growth rates, margins, and operating statistics between your US and UK segments, it appears a discussion of segment information may be material to an understanding of your
Rest of the question

consolidated information. Please advise us. Refer to Rule 303A (and related instructions) of Regulation S-K and the Commission Guidance Regarding Management's Discussion and Analysis of Financial DIVISION OF CORPORATION FINANCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D .C . 20549 Condition and Results of Operations at https://www.sec.gov/rules/interp/33-8350.htm.

ACHC answered
We believe our disclosure complies with Regulation S-K and applicable rules thereunder as the additional segment information in our earnings release is supplemental in nature and not necessary to provide an understanding of our business as a whole. However, in future filings, commencing with our Quarterly Report on Form 10‑Q for the quarter ended June 30, 2018, we intend to expand the discussion of operating results within Management’s Discussion and Analysis of Financial Condition and Results of Operations to include U.S. and U.K. segment information in greater detail.
Read in the reply
In its next report

First report after the company's reply of Jul 10, 2018: 10-Q filed Jul 31, 2018 ↗, against the 10-Q filed May 3, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 2. Summary of Significant Accounting Policies · Insurance, page F-13
SEC asked (2)
We note your insurance subsidiary has obtained reinsurance for professional liability risks of $75 million in excess of a retention level of $3 million. In light of your professional and general liability reserve of $55 million as of December 31, 2017, please explain to us why your reinsurance recoverable was only $22.7 million as of this same date.
Rest of the question

Also, with a view towards clarifying policy disclosure, please tell us if you recognize reinsurance receivables in a manner that is consistent with the related liabilities (including estimates for claims incurred but not reported).

ACHC answered
The Company has obtained reinsurance coverage from a third party to cover losses exceeding coverage limits of insurance policies. For the 2017-2018 policy year, the reinsurance policy has a coverage limit of $75.0 million for claims in the aggregate. The Company had a self-insured coverage limit for professional liability claims of $3.0 million per claim. The majority of our professional liability claims are settled for less than the insurance retention amount.
Rest of the answer

The reinsurance receivable of $22.7 million as of December 31, 2017 is reflective of individual claims that exceed the per claim retention level. In our future filings, we intend to clarify that the $3.0 million self-insured retention limit is on a per claim basis. Our reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies that are in place.

In the event that you have any additional questions, please contact the undersigned at (615) 861-6000.

Read in the reply
In its next report

First report after the company's reply of Jul 10, 2018: 10-Q filed Jul 31, 2018 ↗, against the 10-Q filed May 3, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-07-12

Form 10-K

2017-05-22 to 2017-06-14 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2017-06-14
Non-GAAP measuresIncome taxes
SEC asked
Income Taxes, pages F-27 and F-29 Please tell us the nature of transaction-related items which added 25.9% to your effective 2. tax rate. Please disclose the domestic and foreign components of pre-tax income pursuant to Rule 3. 4-08(h) of Regulation S-X. You state on page F-29 that you intend to utilize undistributed earnings of your foreign 4. subsidiaries in foreign operations for an indefinite period of time.
Rest of the question

However, you also state that at December 31, 2016 there were no undistributed earnings. Please tell us how you utilized the undistributed earnings of your foreign subsidiaries which amounted to approximately $48.0 million at December 31, 2015. Form 8-K filed April 25, 2017 Exhibit 99 Your forward-looking non-GAAP measures on page 2 exclude a quantitative 5. reconciliation in a location of equal or greater prominence. In your year-end earnings release you disclosed your reliance on the “unreasonable efforts” exception in Item 10(e)(1)(i)(B); however, we do not find such reference in the current earnings release. Please revise to comply with the guidance in Question 102.10 of the updated Compliance and Disclosure Interpretation Guidance on non-GAAP financial measures issued on May 17, 2016 in your next earnings release. Please refer to “The Constant Currency Condensed Consolidated Statements of 6. Operations.” We do not believe it is appropriate to present a full non-GAAP income statement in your filings with us, as it may attach undue prominence to the non-GAAP information. Please revise to delete the full non-GAAP income statement presentation in your next earnings release. Please refer to Instruction 2 to Item 2.02 of Form 8-K which states that certain provisions of Item 10(e) of Regulation S-K applies to disclosures under Item 2.02. We also refer you to the guidance in Questions 102.10 and 104.06 of the Compliance and Disclosure Interpretation on Non-GAAP Financial Measures as updated on May 17, 2016.

ACHC answered

No numbered answer found in the reply. Read the reply ↗

In its next report

First report after the company's reply of Jun 2, 2017: 10-Q filed Jul 28, 2017 ↗, against the 10-Q filed Apr 26, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-06-14

Form S-4

2014-03-18 to 2014-04-18 · 1 question · 1 letter from the SEC, 2 from the company
No closing letter
General
SEC asked
We note that you are registering the 6.125% Senior Notes and related guarantees in reliance on our position enunciated in Exxon Capital Holdings Corp., SEC No-Action Letter (April 13, 1988). See also Morgan Stanley & Co. Inc., SEC No-Action Letter (June 5, 1991) and Shearman & Sterling, SEC No-Action Letter (July 2, 1993).
Rest of the question

However, the supplemental letter you have provided dated March 6, 2014 does not contain all the representations required by the no-action letters. Specifically, the company must represent that, with respect to any broker-dealer that participates in the Exchange Offer with respect to Outstanding Securities acquired for its own account as a result of marketmaking activities or other trading activities, each such broker-dealer must confirm that it has not entered into any arrangement or understanding with the company or an affiliate of the company to distribute the Exchange Securities. Please revise your supplemental letter accordingly.

ACHC answered
As discussed with the Staff on March 19, 2014, the Company’s supplemental letter, dated March 6, 2014, included in subsection (C) on the second page of the supplemental letter the representation identified in the Staff’s comment above. Accordingly, no revision of the supplemental letter is needed.

Please be advised that, in the event that the Company requests acceleration of the effective date of the pending registration statement, the

Company will acknowledge the Staff’s position that (i) should the Commission or the Staff, acting pursuant to delegated authority, declare the filing
Rest of the answer

effective, it does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert Staff comments and the declaration of the effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you have any additional questions or comments, please contact the undersigned at (615)

861-6000 or the Company’s legal counsel, James H. Nixon III of Waller Lansden Dortch & Davis, LLP at (615) 850-8855.

Read in the reply

Also in this review: company letter, Apr 18, 2014

Letters without questions

Other letters

UPLOAD and CORRESP
9 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • May 27, 2016 · SEC: will not review the filing · Acadia Healthcare Company, Inc. · Registration Statement on Form S-4 · Filed May 20,...
  • May 27, 2016 · ACHC: letter to the SEC · Acadia Healthcare Company, Inc. · Registration Statement on Form S-4 · File Number 333-211503
  • May 20, 2016 · ACHC: letter to the SEC · Acadia Healthcare Company, Inc. Registration Statement on Form S-4 filed on May 20, 2016
  • Oct 20, 2015 · SEC: will not review the filing · Acadia Healthcare Company, Inc. · Registration Statement on Form S-4 · Filed October...
  • Oct 20, 2015 · ACHC: letter to the SEC · Acadia Healthcare Company, Inc. · Registration Statement on Form S-4 · File Number 333-207374
  • Jul 14, 2015 · SEC: will not review the filing · Acadia Healthcare Company, Inc. · Registration Statement on Form S-4 · Filed July 2,...
  • Jul 15, 2015 · ACHC: letter to the SEC · Acadia Healthcare Company, Inc. · Registration Statement on Form S-4 · File Number 333-205473
  • Jul 2, 2015 · ACHC: letter to the SEC · Acadia Healthcare Company, Inc. Registration Statement on Form S-4 filed on July 2, 2015
  • Mar 6, 2014 · ACHC: letter to the SEC · Acadia Healthcare Company, Inc. Registration Statement on Form S-4 filed on March 6, 2014

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 30 letters filed since 2014-03-06. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ACHC/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.